Colon perforation during antiangiogenic therapy for malignant glioma

被引:14
作者
Norden, Andrew D. [1 ,2 ,3 ]
Drappatz, Jan [1 ,2 ,3 ]
Ciampa, Abigail Slate [1 ]
Doherty, Lisa [1 ]
LaFrankie, Debra Conrad [1 ]
Kesari, Santosh [1 ,2 ,3 ]
Wen, Patrick Y. [1 ,2 ,3 ]
机构
[1] Dana Farber Canc Inst, Ctr Neurooncol, Dept Med Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Brigham & Womens Hosp, Dept Neurol, Div Neurooncol, Boston, MA 02115 USA
关键词
antiangiogenic drugs; bevacizumab; gastrointestinal perforation; malignant glioma; PHASE-II TRIAL; COLORECTAL-CANCER; BOWEL PERFORATION; BEVACIZUMAB; IRINOTECAN; CORTICOSTEROIDS; STEROIDS;
D O I
10.1215/15228517-2008-071
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Antiangiogenic drugs have emerged as effective treatment options for patients with recurrent malignant gliomas (MGs). Though this class of drugs is generally well tolerated, rare life-threatening complications, including thromboembolism, hemorrhage, and gastrointestinal (GI) perforation, are reported. We describe six cases of GI perforation among 244 glioma patients (2.5%) during treatment with antiangiogenic agents in combination with chemotherapy and corticosteroids. Two patients succumbed to this complication, and the others recovered. Because GI perforation is a life-threatening yet treatable complication, neurooncologists must have a low threshold to consider it in patients on antiangiogenic drug therapy who present with abdominal pain and other GI complaints. Neuro-Oncology 11, 92-95, 2009 (Posted to Neuro-Oncology [serial online], Doc. D08-00073, August 29, 2008. URL http://neuro-oncology.dukejournals.org; DOI: 10.1215/15228517-2008-071)
引用
收藏
页码:92 / 95
页数:4
相关论文
共 17 条
[1]   Management of bevacizumab-associated bowel perforation: a case series and review of the literature [J].
Badgwell, B. D. ;
Camp, E. R. ;
Feig, B. ;
Wolff, R. A. ;
Eng, C. ;
Ellis, L. M. ;
Cormier, J. N. .
ANNALS OF ONCOLOGY, 2008, 19 (03) :577-582
[2]   AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].
Batchelor, Tracy T. ;
Sorensen, A. Gregory ;
di Tomaso, Emmanuelle ;
Zhang, Wei-Ting ;
Duda, Dan G. ;
Cohen, Kenneth S. ;
Kozak, Kevin R. ;
Cahill, Daniel P. ;
Chen, Poe-Jou ;
Zhu, Mingwang ;
Ancukiewicz, Marek ;
Mrugala, Maciej M. ;
Plotkin, Scott ;
Drappatz, Jan ;
Louis, David N. ;
Ivy, Percy ;
Scadden, David T. ;
Benner, Thomas ;
Loeffler, Jay S. ;
Wen, Patrick Y. ;
Jain, Rakesh K. .
CANCER CELL, 2007, 11 (01) :83-95
[3]  
CLOUGHESY T, 2007, SOC NEUR 12 ANN M NO
[4]   A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) [J].
Cloughesy, T. F. ;
Prados, M. D. ;
Wen, P. Y. ;
Mikkelsen, T. ;
Abrey, L. E. ;
Schiff, D. ;
Yung, W. K. ;
Maoxia, Z. ;
Dimery, I. ;
Friedman, H. S. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[5]   PERFORATION OF THE GASTROINTESTINAL-TRACT IN PATIENTS RECEIVING STEROIDS FOR NEUROLOGIC DISEASE [J].
FADUL, CE ;
LEMANN, W ;
THALER, HT ;
POSNER, JB .
NEUROLOGY, 1988, 38 (03) :348-352
[6]   What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? [J].
Han, Ernest S. ;
Monk, Bradley J. .
GYNECOLOGIC ONCOLOGY, 2007, 105 (01) :3-6
[7]  
Heinzerling John H, 2006, Curr Surg, V63, P334, DOI 10.1016/j.cursur.2006.06.002
[8]   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].
Hurwitz, H ;
Fehrenbacher, L ;
Novotny, W ;
Cartwright, T ;
Hainsworth, J ;
Heim, W ;
Berlin, J ;
Baron, A ;
Griffing, S ;
Holmgren, E ;
Ferrara, N ;
Fyfe, G ;
Rogers, B ;
Ross, R ;
Kabbinavar, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342
[9]   Phase II trial of bevacizurnab plus gemcitabine in patients with advanced pancreatic cancer [J].
Kindler, HL ;
Friberg, G ;
Singh, DA ;
Locker, G ;
Nattam, S ;
Kozloff, M ;
Taber, DA ;
Karrison, T ;
Dachman, A ;
Stadler, WM ;
Vokes, EE .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :8033-8040
[10]   USE OF CORTICOSTEROIDS IN NEUROONCOLOGY [J].
KOEHLER, PJ .
ANTI-CANCER DRUGS, 1995, 6 (01) :19-33